Australia's largest stock trading and investment forum Australia's #1 stock forum

KZA

Click for more information

0.00%

8.0¢ kazia therapeutics limited

I understand your concern but I doubt if much can be inferred...

First 100 Last

Share
Profile

Follow
spyglass

1,345 Posts.

141

05/04/22

15:57

Post #: 60664091
Share

Originally posted by DTshares: ↑

Hi all,

Can some perhaps please explain why Pax is an investible drug given these P2 results sit roughly in the middle of Tem in MGMT UNMETHYLATED GBM across recent studies over the last 15ish years, as per below table from Hegi and Stupo, Neuro-Oncology 17(11), 1425–1427, 2015.,

Which is somewhat backed up by Alnahhas et al. metaanalysis of Tem in MGMT UNMETHYLATED GBM in 2020 in Neuro-Oncology Advances 2(1), 1–7, 2020. The finding there is " The median OS for patients with unmethylated GBM treated with RT/TMZ pooled from 5 phase III studies(N = 655) was 14.11 months (95% confidence interval [CI], 13.18–15.04)"

So Pax benefit a lot less than presented by the company?

What am I missing here?

Cheers.

Expand

I understand your concern but I doubt if much can be inferred from a P2 trial given the target of Paxalisib. P3 results based on PI3K mutation (GBM Agile) data is what will make or break Kazia.

KZA Price at posting: $1.10 Sentiment: Hold Disclosure: Held
3 Upvote

0 Great analysis

Reply

There are more pages in this discussion • 8 more messages in this thread...

First 100 Last

Add KZA (ASX) to my watchlist

SPONSORED BY